An international research consortium reported engineering a bacterial strain that overcomes long‑standing molecular bottlenecks in doxorubicin biosynthesis, enabling markedly higher yields of the chemotherapy agent. The work, published in Nature Communications, addresses challenges that have limited microbial production of anthracyclines for more than five decades. Teams mapped and rewired biosynthetic pathways, resolving rate‑limiting enzymatic steps and enabling scalable production routes. Authors argue the advance could ease supply constraints and lower manufacturing complexity for a cornerstone cancer drug. Sources: Nature Communications papers and consortium press materials.